• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用西罗莫司治疗纤维脂肪血管异常:两名患者取得成功结果。

Fibroadipose vascular anomaly treated with sirolimus: Successful outcome in two patients.

作者信息

Erickson Jonathan, McAuliffe William, Blennerhassett Lewis, Halbert Anne

机构信息

Department of Dermatology, Princess Margaret Hospital for Children, Perth, WA, Australia.

Neurological Intervention and Imaging Service of Western Australia, Sir Charles Gairdner Hospital, Perth, WA, Australia.

出版信息

Pediatr Dermatol. 2017 Nov;34(6):e317-e320. doi: 10.1111/pde.13260.

DOI:10.1111/pde.13260
PMID:29144050
Abstract

Fibroadipose vascular anomaly (FAVA) is a rare, complex mesenchymal malformation combining fibrofatty replacement of the affected muscles and slow-flow vascular malformation. The condition is characterized by localized swelling, severe pain, phlebectasia, and contracture of the affected limb. Treatment paradigms are not well established for this rare, recently recognized condition. We report two cases of FAVA in which treatment with sirolimus produced rapid, dramatic improvement in pain and quality of life.

摘要

纤维脂肪性血管异常(FAVA)是一种罕见的复杂间充质畸形,它将受累肌肉的纤维脂肪替代与缓慢血流的血管畸形结合在一起。这种疾病的特征是局部肿胀、剧痛、静脉扩张以及受累肢体挛缩。对于这种罕见的、最近才被认识的疾病,治疗模式尚未明确确立。我们报告了两例FAVA病例,其中西罗莫司治疗使疼痛和生活质量迅速、显著改善。

相似文献

1
Fibroadipose vascular anomaly treated with sirolimus: Successful outcome in two patients.用西罗莫司治疗纤维脂肪血管异常:两名患者取得成功结果。
Pediatr Dermatol. 2017 Nov;34(6):e317-e320. doi: 10.1111/pde.13260.
2
Successful Treatment of Fibro-Adipose Vascular Anomaly with Sirolimus.西罗莫司成功治疗纤维脂肪血管异常
J Pediatr Surg. 2023 Jul;58(7):1337-1341. doi: 10.1016/j.jpedsurg.2023.01.063. Epub 2023 Feb 15.
3
Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.西罗莫司治疗广泛和/或复杂慢血流血管畸形有效:单中心前瞻性 II 期研究。
Orphanet J Rare Dis. 2018 Oct 29;13(1):191. doi: 10.1186/s13023-018-0934-z.
4
Fibro-adipose vascular anomaly (FAVA) - diagnosis, staging and management.纤维脂肪性血管异常(FAVA) - 诊断、分期和管理。
Orphanet J Rare Dis. 2023 Nov 7;18(1):347. doi: 10.1186/s13023-023-02961-6.
5
Fibro-adipose vascular anomaly: clinical-radiologic-pathologic features of a newly delineated disorder of the extremity.纤维脂肪血管异常:一种新定义的肢体疾病的临床-放射学-病理学特征
J Pediatr Orthop. 2014 Jan;34(1):109-17. doi: 10.1097/BPO.0b013e3182a1f0b8.
6
Surgical Management of Fibroadipose Vascular Anomaly of the Lower Extremities.下肢纤维脂肪血管异常的手术治疗
J Pediatr Orthop. 2020 Mar;40(3):e227-e236. doi: 10.1097/BPO.0000000000001406.
7
Topical sirolimus for treatment of a venolymphatic malformation in an adolescent girl.外用西罗莫司治疗一名青春期女孩的静脉淋巴管畸形。
Pediatr Dermatol. 2018 Nov;35(6):e406-e407. doi: 10.1111/pde.13622. Epub 2018 Aug 28.
8
Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.西罗莫司治疗巨大复杂浅表性慢血流血管畸形(PERFORMUS):一项采用随机观察阶段设计的多中心2期试验方案
Trials. 2018 Jun 27;19(1):340. doi: 10.1186/s13063-018-2725-1.
9
Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series.外用西罗莫司治疗儿童血管异常的疗效与吸收:病例系列
Pediatr Dermatol. 2018 Jul;35(4):472-477. doi: 10.1111/pde.13547. Epub 2018 May 23.
10
Sirolimus for the treatment of complicated vascular anomalies in children.西罗莫司治疗儿童复杂血管畸形。
Pediatr Blood Cancer. 2011 Dec 1;57(6):1018-24. doi: 10.1002/pbc.23124. Epub 2011 Mar 28.

引用本文的文献

1
Diagnosis and Oral Sirolimus Treatment of Fibro-Adipose Vascular Anomaly in Pediatric Patients: A Case Series and Comprehensive Review.小儿纤维脂肪性血管异常的诊断与口服西罗莫司治疗:病例系列及综合综述
Paediatr Drugs. 2025 Mar 8. doi: 10.1007/s40272-025-00686-6.
2
Clinicopathological Characteristics, Gene Mutations, and Treatment of Fibro-adipose Vascular Anomaly: A Case Series From China and Literature Review.纤维脂肪性血管异常的临床病理特征、基因突变及治疗:来自中国的病例系列及文献综述
Ann Plast Surg. 2025 May 1;94(5):581-588. doi: 10.1097/SAP.0000000000004303. Epub 2025 Feb 24.
3
Progress about the fibro-adipose vascular anomaly: A review.
纤维脂肪血管异常的研究进展:综述。
Medicine (Baltimore). 2024 Feb 16;103(7):e37225. doi: 10.1097/MD.0000000000037225.
4
Fibro-adipose vascular anomaly (FAVA) - diagnosis, staging and management.纤维脂肪性血管异常(FAVA) - 诊断、分期和管理。
Orphanet J Rare Dis. 2023 Nov 7;18(1):347. doi: 10.1186/s13023-023-02961-6.
5
A Report of a Rare Case of Multiple Fibro adipose Venous Anomaly.一例罕见的多发性纤维脂肪静脉畸形病例报告。
J Orthop Case Rep. 2022 Jun;12(6):19-22. doi: 10.13107/jocr.2022.v12.i06.2848. Epub 2022 Jun 10.
6
Fibro-Adipose Vascular Anomaly: A Case Report and Literature Review.纤维脂肪血管异常:一例报告及文献综述
Cureus. 2022 Oct 27;14(10):e30757. doi: 10.7759/cureus.30757. eCollection 2022 Oct.
7
Radiomics-based machine learning approach in differentiating fibro-adipose vascular anomaly from venous malformation.基于影像组学的机器学习方法在鉴别纤维脂肪血管畸形与静脉畸形中的应用
Pediatr Radiol. 2023 Mar;53(3):404-414. doi: 10.1007/s00247-022-05520-6. Epub 2022 Oct 22.
8
Case Report of Fibro-Adipose Vascular Anomaly (FAVA) with Activating Somatic Mutation.伴有体细胞激活突变的纤维脂肪血管异常(FAVA)病例报告
Case Rep Genet. 2022 Aug 2;2022:9016497. doi: 10.1155/2022/9016497. eCollection 2022.
9
Fibro Adipose Vascular Anomaly: A Rare and Often Misdiagnosed Entity.纤维脂肪血管异常:一种罕见且常被误诊的病症。
Indian J Radiol Imaging. 2021 Nov 13;31(3):776-781. doi: 10.1055/s-0041-1736399. eCollection 2021 Jul.
10
Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study.低剂量 PI3K 抑制剂 taselisib 在患有 CLOVES 和 Klippel-Trenaunay 综合征(KTS)的成年患者中的安全性和疗效:TOTEM 试验,一项 1/2 期、多中心、开放标签、单臂研究。
Genet Med. 2021 Dec;23(12):2433-2442. doi: 10.1038/s41436-021-01290-y. Epub 2021 Aug 12.